Plain-English translation of NCT04196257 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 1 — Testing in a small group (usually 20–80 people) to find a safe dose and watch for side effects.
This trial is testing a new medication called BP1001-A, which works by blocking a protein that helps cancer cells grow. The study will first test the medication alone to find the safest dose, then combine it with a standard chemotherapy drug called paclitaxel to see if the combination works better for treating advanced or recurrent gynecologic cancers.
Many patients with advanced ovarian, endometrial, and related cancers run out of effective treatment options. This medication targets a specific protein involved in cancer cell growth, and researchers hope combining it with existing chemotherapy may offer a new option for patients who have limited choices.
You likely qualify if…
You likely don't qualify if…
The study has two phases. In the first phase, you would receive the new medication alone at increasing doses to find the safest level. Once a safe dose is found, the second phase begins where eligible participants receive the medication combined with paclitaxel chemotherapy. Throughout the study, you will have blood tests, imaging scans, and tumor biopsies taken before and after treatment to see how the medication is working and to monitor for side effects.
AI-generated summary from trial data · Jun 18, 2026 · Not medical advice
United States